Ucello Therapeutics
About:
Ucello Therapeutics is engaged in development of allogeneic cell therapies using its proprietary CAR-T cell technology platform CBT-X20.
Website: http://www.ucello.cn/
Top Investors: Matrix Partners China, Northern Light Venture Capital, Cowin Venture, Chengdu Tianfu International Bio-Town Investment & Development, Elikon Venture
Description:
Ucello Therapeutics is engaged in development of allogeneic cell therapies using its proprietary CAR-T cell technology platform CBT-X20.
Total Funding Amount:
$60.3M
Estimated Revenue Range:
$10M to $50M
Headquarters Location:
Chengdu, Sichuan, China
Founded Date:
2020-12-01
Contact Email:
ucello(AT)ucellotx.com
Founders:
Number of Employees:
1-10
Last Funding Date:
2023-06-02
IPO Status:
Private
Industries:
© 2025 bioDAO.ai